Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Salmanton-García, Jon  [Clear All Filters]
2024
Salmanton-García J, Marchesi F, Farina F, Weinbergerova B, Itri F, Dávila-Valls J, Martín-Pérez S, Glenthøj A, Hersby DStampe, da Silva MGomes, et al. Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022. EClinicalMedicine. 2024;71:102553.
Aiello TFrancesco, Salmanton-García J, Marchesi F, Weinbergerova B, Glenthoj A, van Praet J, Farina F, Dávila-Valls J, Martín-Pérez S, El-Ashwah S, et al. Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA Registry. Haematologica. 2024.
Lahmer T, Salmanton-García J, Marchesi F, El-Ashwah S, Nucci M, Besson C, Itri F, Jaksic O, Čolović N, Weinbergerova B, et al. Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey. Infection. 2024.
2023
Salmanton-García J, Hoenigl M, Salzer HJF, Lackner M, Prattes J, Dichtl K, Winkler-Zamani M, Krause R, Stemler J, Lass-Flörl C, et al. The Austrian landscape of diagnostic capacity and access to treatment for invasive fungal infections. Mycoses. 2023.
Salmanton-García J, Marchesi F, Koehler P, Weinbergerova B, Colović N, Falces-Romero I, Buquicchio C, Farina F, VAN Praet J, Biernat MM, et al. MOLNUPIRAVIR COMPARED TO NIRMATRELVIR/RITONAVIR FOR COVID-19 IN HIGH-RISK PATIENTS WITH HAEMATOLOGICAL MALIGNANCY IN EUROPE. A MATCHED-PAIRED ANALYSIS FROM THE EPICOVIDEHA REGISTRY. Int J Antimicrob Agents. 2023:106952.
El-Ashwah S, Salmanton-García J, Bilgin YM, Itri F, Žák P, Weinbergerova B, Verga L, Omrani AS, da Silva MGomes, Szotkowski T, et al. The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey. Leuk Lymphoma. 2023:1-10.
Musto P, Salmanton-García J, Sgherza N, Bergantim R, Farina F, Glenthøj A, Seval GCengiz, Weinbergerova B, Bonuomo V, Bilgin YM, et al. Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the epicovideha registry. Hematol Oncol. 2023.
Salmanton-García J, Marchesi F, Itri F, Farina F, Hoenigl M, Cordoba R, El-Ashwah S, Busca A, Criscuolo M, Cornely OA, et al. Unveiling the Hidden Burden: From EPICOVIDEHA to EPIFLUEHA, Exploring the Epidemiology of Respiratory Viral Infections in Hematological Patients. Hemasphere. 2023;7(11):e970.
2022
Lamure S, Salmanton-García J, Marieton ERobin, Jaksic O, Kohn M, Marchesi F, Marchetti M, El-Ashwah S, Demirkan F, Valković T, et al. COVID-19 and Hairy-Cell Leukemia: An EPICOVIDEHA Survey. Blood Adv. 2022.
2019
Biehl LM, Higgins P, Wille T, Peter K, Hamprecht A, Peter S, Dörfel D, Vogel W, Häfner H, Lemmen S, et al. Impact of single room contact precautions on hospital-acquisition and transmission of multidrug-resistant Escherichia coli: a prospective multicentre cohort-study in haematological and oncological wards. Clin Microbiol Infect. 2019.
Stemler J, Salmanton-García J, Seidel D, Alexander B, Bertz H, Hoenigl M, Herbrecht R, Meintker L, Meißner A, Mellinghoff SC, et al. Risk factors and mortality in invasive Rasamsonia spp. infection: Analysis of cases in the FungiScope® registry and from the literature. Mycoses. 2019.